Life AI Net
الرئيسية
الأرشيف
الحاسبات
الدليل
النشرة البريدية
تسجيل الدخول
العربية
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
الرئيسية
الأرشيف
الحاسبات
الدليل
النشرة البريدية
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
تسجيل الدخول
الرئيسية
الأرشيف
الحاسبات
الدليل
More
مباشر
BioPharma Dive
Two biotechs raise a combined $556M in latest spurt of IPOs
Thermo Fisher
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Illumina
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Science
Deepfakes are everywhere. The godfather of digital forensics is fighting back
Endpoints News
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
Endpoints News
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
10x Genomics Blog
Why 10x Genomics Stock Is Surging Today - TipRanks
FierceBiotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Endpoints News
House panel calls to ban China trial data from FDA drug trial applications
Endpoints News
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
Endpoints News
Supreme Court questions how far generics makers can go with 'skinny label' drugs
Illumina
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView
BioPharma Dive
Two biotechs raise a combined $556M in latest spurt of IPOs
Thermo Fisher
How Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo Finance
Illumina
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Science
Deepfakes are everywhere. The godfather of digital forensics is fighting back
Endpoints News
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
Endpoints News
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
10x Genomics Blog
Why 10x Genomics Stock Is Surging Today - TipRanks
FierceBiotech
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
Endpoints News
House panel calls to ban China trial data from FDA drug trial applications
Endpoints News
Court dismisses part of Lilly lawsuit against Empower, some claims can proceed
Endpoints News
Supreme Court questions how far generics makers can go with 'skinny label' drugs
Illumina
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView
الأرشيف
GCC
٢٢ مايو ٢٠٢٣
BIOTECH PROGRAM - glendale.edu
BIOTECH PROGRAM - glendale.edu
المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.